Compare MYO & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | CCEL |
|---|---|---|
| Founded | 2004 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 32.7M |
| IPO Year | 2017 | 2022 |
| Metric | MYO | CCEL |
|---|---|---|
| Price | $0.72 | $2.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $7.67 | N/A |
| AVG Volume (30 Days) | ★ 413.9K | 8.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.19% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000,000.00 | $25,384,279.00 |
| Revenue This Year | $15.92 | N/A |
| Revenue Next Year | $21.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40814.79 | 9.76 |
| 52 Week Low | $0.63 | $2.89 |
| 52 Week High | $5.62 | $6.79 |
| Indicator | MYO | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 30.08 |
| Support Level | $0.64 | N/A |
| Resistance Level | $1.03 | $3.57 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 42.38 | 18.87 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.